Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | ACP1 | P24666 | 1/20 | 0.48 |
| ▸ | RAD52 | P43351 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GBA1 | P04062 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MERTK | Q12866 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1289393 | 0.90 | POLB (0.52) | PDE5AMEN1KMT2AMAPK1MAPT | |
| SCHEMBL1289430 | 0.88 | ALDH1A1 (0.65) | KMT2AMAPK1ACP1RAD52POLB | |
| Hydrochloric Acid SCHEMBL4507915 | 0.87 | ALDH1A1 (0.67) | KMT2AMAPK1ACP1RAD52POLB | |
| SCHEMBL1289384 | 0.86 | POLB (0.66) | PDE5AKMT2AMAPK1ACP1RAD52 | |
| SCHEMBL1289460 | 0.85 | POLB (0.56) | PDE5AKMT2AMAPK1ACP1RAD52 | |
| Hydrochloric Acid SCHEMBL4512327 | 0.85 | POLB (0.68) | KMT2AMAPK1ACP1RAD52POLB | |
| SCHEMBL12473363 | 0.84 | ALDH1A1 (0.60) | PDE5AKMT2AMAPK1ACP1RAD52 | |
| Hydrochloric Acid SCHEMBL4500478 | 0.84 | ALDH1A1 (0.62) | PDE5AKMT2AMAPK1ACP1RAD52 | |
| SCHEMBL1289397 | 0.83 | ACP1 (0.67) | MEN1KMT2AMAPK1MAPTNPSR1 | |
| SCHEMBL1289433 | 0.83 | TLR9 (0.62) | PDE5AKMT2AMAPK1ACP1RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | TP53, AZI2, MCL1 | PDE5A 2492/4885MEN1 1322/4885KMT2A 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.